Popular Articles

Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties Of TAK-652 For The Treatment Of HIV
Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two Phase I pharmacokinetic studies for TAK-652, an investigational compound being developed for the treatment of HIV. These data suggest that TAK-652 is rapidly absorbed and demonstrate relatively good oral bioavailability (as shown by the plasma TBR-652 concentration data) and has a long plasma half-life of TBR-652 (approximate mean of 35 hours) supporting once-daily dosing. Mean TBR-652 plasma concentrations were well above the predicted target plasma concentration (2ng/mL) with or without food. In both studies TBR-652 was safe and well tolerated in this healthy subject population when administered over a dose range of 10 mg to 800 mg in 2 tablet formulations. "These two Phase I studies provide encouraging support for TAK-652 as a therapeutic option for the treatment of HIV. We look forward to results from our on-going proof-of-concept study," said James Sapirstein, CEO.
generic viagra online
Scientists Search For Sleepless Souls Suffering Lifelong Insomnia, Scotland
Most people have experienced the odd sleepless night before a crucial exam, a job interview or before going on holiday, but few people get by with just a couple of hours of sleep a day, every day.
News of the day
The Royal Society For Public Health Announces It Will Be Delivering Training Sessions
The Royal Society for Public Health (RSPH) announces it will be delivering training sessions for the RSPH Level 1 Health Awareness and the RSPH Level 2 Understanding Health Improvement awards.
Public Health

New Way To Enhance Stem Cells To Stimulate Muscle Regeneration Discovered By Ottawa Scientists

Scientists at the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa have discovered a powerful new way to stimulate muscle regeneration, paving the way for new treatments for debilitating conditions such as muscular dystrophy. The research, to be published in the June 5 issue of Cell Stem Cell, shows for the first time that a protein called Wnt7a increases the number of stem cells in muscle tissue, leading to accelerated growth and repair of skeletal muscle. "This discovery shows us that by targeting stem cells to boost their numbers, we can improve the body"s ability to repair muscle tissue," said senior author Dr. Michael Rudnicki. Dr. Rudnicki is the Scientific Director of Canada"s Stem Cell Network and a Senior Scientist at OHRI and Director of OHRI"s Sprott Centre for Stem Cell Research, as well as a Professor of Medicine at the University of Ottawa. Stem cells give rise to every tissue and organ in the body. Satellite stem cells are specialized muscle stem cells that live in adult skeletal muscle tissue and have the ability to both replicate and differentiate into various types of muscle cells. Dr. Rudnicki"s team found that the Wnt7a protein, when introduced into mouse muscle tissue, significantly increased the population of these satellite stem cells and fueled the regeneration process, creating bigger and stronger muscles. Muscle tissue mass was increased by nearly 20 per cent in the study. "Our findings point the way to the development of new therapeutic treatment for muscular diseases such as muscular dystrophy, sarcopenia and muscle wasting conditions resulting from extended hospital stays and surgeries," said Dr. Rudnicki. This project was funded by the Canadian Institutes of Health Research, the Muscular Dystrophy Association, the National Institutes of Health, the Howard Hughes Medical Institute, Canada"s Stem Cell Network and the Canada Research Chairs Program. Jennifer Paterson Ottawa Hospital Research Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):